Policy / Pricing Trump backs psychedelics for mental health in new executive order Pharmaceutical TechnologyTrump's executive order sets out to speed up the review of psychedelics, while supporting research into this burgeoning field.Policy / PricingNeuroscienceRead full story pharminent April 20, 2026 (Last updated: April 20, 2026) Pharmaceutical Technology Trump’s executive order sets out to speed up the review of psychedelics, while supporting research into this burgeoning field. Policy / PricingNeuroscienceRead full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: UCB to purchase Neurona and NRTX-1001 for $1.15bnNext: AZ is three for three with COPD hope tozorakimab Related Stories Policy / Pricing US launches probe of German ‘underpayment’ for medicines pharminent June 19, 2026 Policy / Pricing FDA’s new voucher program hints at broader policy agenda, making many ‘uncomfortable’ pharminent June 19, 2026 Policy / Pricing German said to be backtracking on pharma rebate changes pharminent June 16, 2026
